Leukotrienes Inflammation and Immune Response: A Survey

www.surveyx.cn

Abstract

This survey paper explores the intricate roles of leukotrienes, potent lipid mediators derived from arachidonic acid, in modulating inflammation and immune responses. Leukotrienes significantly influence both innate and adaptive immune dynamics, impacting cellular recruitment, cytokine production, and signaling pathways. Their involvement in diseases such as asthma, arthritis, metabolic disorders, and cancer underscores the complexity of their regulatory mechanisms and potential therapeutic implications. Recent advancements in single-cell RNA sequencing and computational modeling have enriched our understanding of leukotriene pathways, revealing novel insights into their roles in maintaining immune homeostasis and regulating pathogen colonization. The paper highlights the therapeutic potential of leukotriene inhibitors, such as montelukast, in managing inflammatory conditions and explores emerging therapies targeting leukotriene biosynthesis and signaling pathways. The integration of multi-omics and computational tools is emphasized as a frontier for advancing research and developing personalized medicine strategies. Future research directions include elucidating leukotriene interactions in severe infections, exploring probiotics for gut microbiota modulation, and investigating the vagus nerve's role in immunometabolic regulation. This comprehensive analysis underscores the importance of understanding leukotriene-mediated inflammation for developing targeted interventions, ultimately improving clinical outcomes in inflammatory and immune-mediated diseases.

1 Introduction

1.1 Interconnected Biological Processes

Leukotrienes, lipid mediators derived from arachidonic acid, are pivotal in mediating the interplay between inflammation and the immune system. These bioactive molecules influence both innate and adaptive immune responses, functioning to promote inflammation while modulating immune cell activity [1]. Their biosynthesis is closely linked to enzymatic pathways that regulate inflammatory processes, underscoring their role in immune modulation.

The interactions involving leukotrienes and the immune system are complex and involve various cellular and molecular components. For instance, leukotrienes modulate the NF-kappaB signaling pathway, which is critical for immune responses, affecting the transcription of genes related to inflammation and immune regulation [2]. They also impact mitochondrial function in immune cells, thereby influencing cellular metabolism and the overall immune response [3].

Recent advancements in single-cell RNA sequencing have provided insights into cell type dynamics, revealing previously unrecognized pathways in tissue development [4]. This technological progress highlights the need for innovative approaches to fully understand leukotriene-influenced pathways. Notably, leukotrienes play a significant role in gut microbiota interactions, regulating pathogen colonization and maintaining immune homeostasis [5], thereby bridging microbial signals and host immune responses.



Figure 1: chapter structure

Leukotrienes are also crucial in neuroinflammation, particularly through glial cell activation, emphasizing their dual role in promoting and resolving inflammation within the central nervous system [6]. In pathological contexts like sepsis, characterized by a dysregulated immune response, leukotrienes are critical due to their involvement in tissue damage and high mortality rates [7]. Additionally, in tumor-associated inflammation, leukotrienes influence tumor growth and the tumor microenvironment, illustrating their role in both tumor promotion and inhibition.

These intricate immune cell interaction networks enhance the body's defense mechanisms through the coordinated action of cytokines, chemokines, and hormones. However, dysregulation within these networks due to factors like chronic stress can lead to chronic inflammation and contribute to stress-related diseases, including cardiovascular issues, metabolic disorders, and depression [8, 9, 10, 11, 12]. A comprehensive understanding of these processes is essential for developing targeted therapeutic strategies to modulate leukotriene activity, thereby enhancing clinical outcomes in inflammatory and immune-mediated diseases.

1.2 Significance in Health and Disease

Leukotrienes are vital mediators in maintaining physiological homeostasis and play significant roles in the pathogenesis of various diseases. As potent lipid mediators, they are integral to regulating immune responses and metabolic processes, underscoring their importance in health and disease [13]. Their involvement in energy regulation and macromolecular processes is crucial in preventing metabolic disorders such as obesity and diabetes, where dysregulated leukotriene activity can exacerbate inflammatory pathways [14].

In inflammatory diseases, leukotrienes are central to immune response dynamics within the gut microbiota, influencing pathogen colonization and immune responses, particularly in conditions like Inflammatory Bowel Disease (IBD) [15]. In neuroinflammatory conditions such as ischemic stroke, leukotrienes interact with glial cells to modulate immune responses, impacting both neuroprotection and neurodegeneration [16]. Their role in Alzheimer's disease progression, through interactions with microglial cells and interleukins, highlights the complexity of inflammation in neurodegenerative disorders [17].

The COVID-19 pandemic has further emphasized the role of leukotrienes in disease pathogenesis, particularly in the post-acute phase where persistent inflammation poses significant health challenges [18]. Monitoring leukotriene levels as inflammatory biomarkers is critical for timely intervention and improved patient outcomes in post-COVID-19 conditions [19]. A balanced immune response mediated by leukotrienes is essential in viral infections to prevent tissue damage while controlling viral replication [1].

Chronic inflammation, influenced by leukotrienes, contributes to disparities observed in coronary heart disease among different racial and socioeconomic groups, where social hierarchies exacerbate adverse cardiovascular outcomes [20]. In sepsis, characterized by dysregulated immune responses, leukotrienes are key players in the inflammatory cascade, contributing to the high mortality rate of 28-50% [7].

In cancer, leukotrienes are implicated in both tumor promotion and prevention. Their interaction with phytochemicals highlights their dual role in cancer pathogenesis, where they can either facilitate tumor growth or aid in chemoprevention strategies [15]. The complexity of leukotriene-mediated pathways and their high-dimensionality in biochemical networks present challenges for understanding their complete impact on immune response dynamics and disease progression [13].

Additionally, C-reactive protein (CRP), often associated with inflammation, actively participates in immune responses, with its isoforms playing distinct roles that warrant further investigation [21]. A comprehensive understanding of leukotrienes is essential for developing effective therapeutic strategies and enhancing clinical outcomes in inflammatory and immune-mediated diseases.

1.3 Structure of the Survey

This survey is organized into several key sections that systematically explore the intricate roles of leukotrienes in inflammation and immune response. The introductory section provides an overview of the interconnected biological processes involving leukotrienes, emphasizing their significance in both health and disease contexts. This is followed by a detailed background section that delves into the biosynthesis of leukotrienes from arachidonic acid and their function as inflammatory mediators, elucidating the general mechanisms of inflammation and immune response dynamics. The interplay between these processes sets the stage for subsequent discussions.

The core of the survey is divided into two main thematic areas: the role of leukotrienes in inflammation and their influence on the immune response. The section on leukotrienes and inflammation examines their specific involvement in various inflammatory diseases, focusing on recent research findings related to leukotriene pathways and their regulation. The subsequent section on leukotrienes and the immune response explores how these mediators affect immune cell dynamics, cytokine production, and immune signaling pathways, providing examples of diseases characterized by leukotriene-mediated immune dysregulation.

Therapeutic implications are addressed in a dedicated section that reviews current treatments involving leukotriene inhibitors, evaluates their efficacy, and discusses emerging therapies targeting leukotriene pathways. The survey concludes with a synthesis of key points, reflections on the importance of understanding leukotrienes in inflammation and immune response, and an exploration of potential areas for future research and clinical practice implications. This structured approach ensures a comprehensive and coherent exploration of the topic, facilitating a deeper understanding of the multifaceted roles of leukotrienes.The following sections are organized as shown in Figure 1.

2 Background

2.1 Leukotriene Biosynthesis and Function

Leukotrienes, derived from arachidonic acid via enzymatic reactions, play a critical role in regulating inflammatory and immune responses. This biosynthesis begins with arachidonic acid's release from membrane phospholipids, catalyzed by phospholipase A2, and its conversion into leukotriene A4 (LTA4) by 5-lipoxygenase (5-LO) and 5-lipoxygenase activating protein (FLAP) [22]. LTA4, an unstable intermediary, can transform into leukotriene B4 (LTB4) through LTA4 hydrolase or into cysteinyl leukotrienes (LTC4, LTD4, and LTE4) via LTC4 synthase [23].

Leukotrienes are pivotal in both acute and chronic inflammation. LTB4 acts as a potent chemoattractant for neutrophils, facilitating their migration and adherence to endothelial cells, crucial for pathogen clearance [24, 14]. Cysteinyl leukotrienes, on the other hand, increase vascular permeability and induce bronchoconstriction, significantly impacting asthma and allergic reactions [23]. In chronic inflammation, leukotrienes influence immune responses, notably in neuroinflammation and ischemic stroke, affecting glial cell activity [25]. They are also implicated in cardiovascular and metabolic disorders, underscoring their physiological significance and therapeutic potential [22].

Advances in computational modeling, particularly integrating protein-protein interaction networks in macrophages, have enhanced our understanding of leukotriene pathways [9]. Such models identify critical variables in leukotriene biosynthesis, offering insights for therapeutic interventions [26]. Mass spectrometry's expansion of eicosanoid profiles, including leukotrienes, further deepens our comprehension of their biological roles [27]. The synthesis and function of leukotrienes underscore their vital role in inflammatory responses, making them attractive therapeutic targets in various diseases. Frameworks like TagHort enhance inflammation prediction models, providing insights into populations affected by leukotriene-mediated processes [11].

2.2 Mechanisms of Inflammation

Inflammation is a complex biological response to harmful stimuli, aimed at eliminating injury sources and initiating tissue repair. It involves a network of molecular and cellular signals essential for homeostasis and infection protection [28]. However, inflammation's unpredictability complicates treatment, especially in conditions like sepsis, where excessive inflammation can cause tissue damage and organ dysfunction [29].

Inflammation is classified into acute and chronic types. Acute inflammation is characterized by a rapid response involving neutrophils migrating to injury sites, marked by pro-inflammatory cytokines and chemokines release, facilitating immune cell recruitment and activation. Effective resolution requires immune cell clearance and tissue homeostasis restoration; otherwise, chronic inflammation may ensue, leading to diseases like cardiovascular conditions, cancer, and neurodegenerative disorders [6]. Chronic inflammation involves sustained pro-inflammatory mediator release, evident in post-COVID-19 inflammation, necessitating effective monitoring and intervention [30].

Inflammation regulation involves intricate signaling pathways. The NF-kappaB pathway mediates inflammatory responses by regulating immune and inflammatory gene expression [31]. The autonomic nervous system significantly modulates responses during pathogen challenges [32], with the vagus nerve's role in glucosensing illustrating neural and immune response interconnectedness [33].

Modeling and computational advancements have improved our understanding of inflammation. Mathematical models simulate chondrocyte-cytokine interactions during injury, elucidating cytokine dynamics [34]. Yet, existing models face calibration challenges due to inflammation type and patient parameter variations, necessitating innovative approaches [35]. The dynamic responses of immune, endocrine, and cardiovascular systems to endotoxin exposure highlight immune system complexity [36].

While inflammation is crucial for infection defense, dysregulation can lead to chronic diseases like atherosclerosis, non-alcoholic fatty liver disease, and depression. This dual nature emphasizes inflammation's role in homeostasis, while highlighting risks of excessive inflammation exacerbating stress-related conditions [8, 28, 32, 36]. Understanding inflammation mechanisms is vital for developing targeted therapies to effectively modulate this response and improve disease outcomes.

2.3 Immune Response Dynamics

The immune response is a dynamic system characterized by intricate interactions between innate and adaptive components, essential for pathogen recognition and elimination while maintaining homeostasis. The innate immune response rapidly identifies pathogens through pattern recognition receptors, triggering inflammation to contain infections [1]. The adaptive response follows, marked by specificity and memory, allowing targeted responses upon subsequent exposures [37].

Chemotaxis is crucial in immune dynamics, directing immune cells to infection sites via chemical gradients, facilitating pathogen clearance and inflammation resolution [38]. The balance between

pro- and anti-inflammatory signals, integrated by dendritic cells, is vital for maintaining immune homeostasis and preventing excessive inflammation, which can lead to chronic diseases [39].

Immune response dynamics are further complicated by time delays in activation and response, challenging control in rapidly progressing conditions like tumor growth and chronic infections, where timely intervention is critical [40]. Persistent infections, such as Hepatitis B, involve complex innate and adaptive immune interactions, emphasizing the need for comprehensive understanding to develop effective treatments [37].

Population-expression models link population-level dynamics with individual cell behavior, providing insights into immune responses across scales [38]. These models elucidate immune thresholds and external factors' impact, such as medications, which can alter immune response thresholds and lead to autoimmune reactions.

The interaction between immune and neuroendocrine systems is another critical aspect. Mathematical models capturing these interactions highlight immune regulation complexity and therapeutic intervention potential [38]. Patient response heterogeneity, especially in conditions like sepsis, underscores static approaches' inadequacy and emphasizes precision medicine strategies [7].

Quantitative analyses of immune cell networks underscore various mediators' centrality in orchestrating immune responses, highlighting immune interactions' complexity and the necessity for deeper understanding [38]. The dynamic nature of the immune response, with its intricate interplay between inflammation and immune regulation, is pivotal for health maintenance and disease combat, necessitating ongoing research to unravel complexities and develop effective strategies.

2.4 Interplay Between Inflammation and Immune Response

The interplay between inflammation and immune response involves complex interactions, with leukotrienes as pivotal mediators. Cysteinyl leukotrienes (cysLTs) significantly influence eosinophilic disorders by modulating eosinophil activation and survival [23], highlighting their role in balancing pro- and anti-inflammatory processes.

In chronic inflammation, leukotrienes contribute to sustained states, as seen in metabolic disorders like obesity. Leukotriene B4-mediated recruitment and activation of immune cells, such as adipose tissue B2 cells, underscore their role in metabolic inflammation and insulin resistance [27]. This imbalance in immune and metabolic interactions is exacerbated in obesity, where stress and inflammation converge [20].

Leukotrienes modulate immune cell dynamics, particularly macrophage activation. Existing models inadequately capture macrophages' regulatory functions, indicating a need for deeper understanding [26]. Leukotriene-macrophage interactions shape the inflammatory landscape, influencing inflammation initiation and resolution [25].

Leukotrienes' involvement in cellular adhesion and rolling is crucial for immune cell recruitment during inflammation [24]. The complexity of these interactions and individual variability present challenges in establishing comprehensive models accurately reflecting immune system behavior [20].

In diseases like COVID-19, leukotrienes are implicated in dysregulated immune responses in severe cases. Understanding leukotriene-mediated inflammation dynamics is crucial for developing effective interventions to mitigate COVID-19's adverse effects [19]. Persistent inflammation in post-COVID-19 conditions underscores the need for targeted therapies addressing leukotriene pathways.

Leukotrienes' dual role in tumor biology further illustrates their complex involvement in immune regulation, as they can promote or inhibit tumor growth, influencing the tumor microenvironment and resistance to immunotherapy [15]. This dichotomous role presents challenges and opportunities in cancer treatment, where modulating leukotriene pathways could enhance therapeutic efficacy [41].

In recent years, the role of leukotrienes in various inflammatory processes has garnered significant attention within the scientific community. Understanding the complex mechanisms through which leukotrienes contribute to inflammation is crucial for developing targeted therapeutic strategies. As illustrated in Figure 2, this figure provides a comprehensive overview of the hierarchical categorization of leukotrienes' roles in inflammation. It delineates their impact on a range of conditions, including respiratory diseases, arthritis, systemic inflammatory conditions, cancer, and metabolic disorders. Furthermore, the figure emphasizes the synthesis and regulation of leukotriene pathways, alongside

the signaling mechanisms involved, thereby encapsulating recent research advancements in the understanding of leukotriene-mediated inflammation. This visual representation not only enhances our comprehension of leukotriene functions but also underscores the need for continued exploration in this pivotal area of study.



Figure 2: This figure illustrates the hierarchical categorization of leukotrienes' roles in inflammation, including their impact on respiratory diseases, arthritis, systemic inflammatory conditions, cancer, and metabolic disorders. It also highlights the synthesis and regulation of leukotriene pathways, signaling mechanisms, and recent research advancements in understanding leukotriene-mediated inflammation.

3 Leukotrienes and Inflammation

3.1 Role of Leukotrienes in Inflammatory Diseases

Leukotrienes are pivotal lipid mediators in inflammatory disease pathogenesis, significantly influencing both local and systemic inflammatory responses. In asthma, leukotriene B4 (LTB4) and cysteinyl leukotrienes (cysLTs) contribute to bronchoconstriction, mucus secretion, and airway inflammation, exacerbating symptoms such as wheezing and shortness of breath. Therapeutic strategies targeting leukotriene pathways, like montelukast, effectively reduce airway inflammation by antagonizing leukotriene receptors, highlighting their importance in asthma management [18].

In arthritis, leukotrienes facilitate immune cell recruitment and activation, intensifying the inflammatory milieu, leading to pro-inflammatory cytokine release and increased vascular permeability, which contribute to joint swelling and pain [14]. The interplay between physical and biochemical factors, such as substrate stiffness affecting leukotriene-mediated cell adhesion, underscores the complexity of inflammatory diseases [34]. Computational models of macrophage behavior in arthritis are crucial for developing effective therapies [26].

Leukotrienes also play roles in systemic inflammatory conditions like lymphedema and sepsis. LTB4 is a significant mediator in lymphedema, emphasizing its role in chronic inflammation [25]. In sepsis, adaptive multi-cytokine therapies tailored to patient-specific responses have been proposed to improve outcomes, with leukotrienes as key components of the inflammatory cascade [7]. Precise biomarker profiling, including leukotrienes, is advocated for managing complex inflammatory diseases, emphasizing categorizing septic states based on biomarker levels instead of solely on clinical symptoms [11].

In cancer, leukotrienes exhibit a dual role in tumor promotion and inhibition, influencing the tumor microenvironment and tumorigenesis. Phytochemicals targeting leukotriene pathways offer promising strategies for modulating tumorigenesis [15]. This dual role presents challenges and opportunities in cancer treatment, where modulating leukotriene pathways could enhance therapeutic efficacy [17].

Leukotrienes also impact metabolic disorders, with modulation presenting therapeutic potential. For instance, the immunomodulatory effects of formulations like Kal-1 have shown promise in alleviating diet-induced obesity and associated metabolic disorders, highlighting the targeting of leukotriene pathways in metabolic inflammation [42].

Leukotrienes are integral to the pathophysiology of various inflammatory diseases, influencing both local and systemic processes. Their modulation represents a promising therapeutic avenue, with ongoing research focused on refining strategies to enhance clinical outcomes across a spectrum of inflammatory conditions [36].

As illustrated in Figure 3, leukotrienes play distinct roles in various inflammatory diseases, categorizing their impacts on asthma, arthritis, and systemic conditions such as lymphedema, sepsis, and cancer. Understanding leukotriene roles in these diseases is crucial for developing targeted therapies that effectively mitigate inflammation and improve patient outcomes.



Figure 3: This figure illustrates the roles of leukotrienes in various inflammatory diseases, categorizing their impacts on asthma, arthritis, and systemic conditions such as lymphedema, sepsis, and cancer.

3.2 Leukotriene Pathways and Regulation

Leukotrienes are synthesized through complex enzymatic pathways involving 5-lipoxygenase (5-LOX) and associated proteins, crucial for mediating inflammation [22]. The biosynthesis begins with the conversion of arachidonic acid into leukotriene A4 (LTA4), a precursor for both LTB4 and cysLTs. These pathways are intricately regulated to maintain precise control over leukotriene production and function in inflammatory responses.

The LTB4-BLT1 signaling pathway is significant for recruiting and activating immune cells, such as neutrophils and macrophages. Recent structural studies have elucidated the agonist-bound structure of the BLT1 receptor, providing insights into ligand binding and receptor activation, distinct from antagonist-bound structures [24]. This structural understanding is pivotal for designing therapeutic interventions targeting the BLT1 receptor in inflammatory diseases.

CysLTs, including LTC4, LTD4, and LTE4, exert effects primarily through the CysLT1 receptor (CysLT1R), essential for modulating immune cell functions and amplifying inflammatory responses. The interaction between CysLTs and interleukin-33 (IL-33) in type 2 innate lymphoid cells (ILC2s) illustrates a critical aspect of immune dynamics, where LTC4 enhances IL-33-induced ILC2 activation and lung inflammation, leading to increased Th2 cytokine production and eosinophilia. Targeting the CysLT1 receptor may provide novel therapeutic strategies for allergic and inflammatory diseases, such as asthma [43, 44, 23, 22, 45].

Advancements in computational modeling and directed non-targeted mass spectrometry have expanded our understanding of leukotriene regulatory mechanisms, revealing over 500 distinct eicosanoid signals in human plasma, including 46 previously unidentified molecules. This enhanced analytical capability elucidates the complex roles of leukotrienes in inflammation and asthma pathophysiology, highlighting potential therapeutic targets within the LTB4-BLT1 pathway, crucial for neutrophil recruitment and T lymphocyte activation [43, 23, 27, 11, 22]. Cellular automaton models exploring noise effects in cytokine signaling offer insights into the NF-B regulatory network, a critical component of leukotriene-mediated inflammation.

Emerging technologies, including deep learning and artificial neural networks, predict inflammatory responses by forecasting cytokine levels and health metrics based on historical data. These computational tools present significant potential for managing leukotriene-mediated inflammation, demonstrated by models that segment images and quantify neutrophils, key indicators of inflammation. Such tools leverage machine learning to automate the identification of inflammatory biomarkers, enhancing the understanding of immune responses and facilitating early interventions in various inflammatory disorders, including those linked to post-COVID-19 conditions and tumor-associated inflammation. By integrating high-throughput imaging analysis and gene expression insights, these models provide a comprehensive approach to assessing inflammatory responses and may ultimately contribute to improved patient care and targeted therapeutic strategies [27, 30, 11, 15, 46].

The pathways and regulatory mechanisms of leukotrienes in inflammation are complex, involving intricate interactions between various signaling pathways and immune cells. Understanding these regulatory networks is crucial for developing targeted therapeutic strategies that effectively modulate leukotriene activity, enhancing clinical outcomes in various inflammatory diseases, particularly asthma and eosinophilic disorders. This is underscored by the established roles of leukotrienes, such as LTB4 and cysLTs, in mediating inflammatory responses and their potential as drug targets, especially in patients with uncontrolled asthma despite corticosteroid treatment [43, 44, 23, 13, 22].

3.3 Recent Research and Emerging Insights

Recent advancements in leukotriene-related inflammation research have unveiled novel insights into regulatory mechanisms and potential therapeutic targets. One significant development is the application of saddle-node in cycle (SNIC) bifurcations, providing a mathematical framework to describe transitions between health and infection states, offering a nuanced understanding of leukotriene-mediated inflammatory responses [47].

Experimental studies have elucidated the critical role of leukotriene pathways in immune cell function. Notably, BLT1 receptor expression on T cells is essential for interleukin-13 (IL-13) production and airway hyperresponsiveness, underscoring leukotriene signaling's importance in respiratory inflammatory diseases [43]. This finding highlights the potential for targeting BLT1 in therapeutic strategies aimed at mitigating airway inflammation.

Integrating chemotaxis into reaction models has provided a more accurate representation of biological processes, particularly enhancing reaction rates in one-dimensional settings, crucial for understanding immune cell migration and activation in response to leukotriene signaling [48].

Single-cell RNA sequencing has emerged as a powerful tool for characterizing cell populations and regulatory pathways. Recent experiments demonstrated its efficacy in revealing the leukotriene pathway as a critical regulator of blood progenitor development in post-gastrulation mammalian embryos, emphasizing leukotrienes' role in hematopoiesis and immune cell differentiation [4].

In viral infections, combining antiviral drugs targeting replication with immune response enhancers has shown significant efficacy in reducing viral load and infected cell populations. This approach highlights the potential for integrating leukotriene pathway modulators into antiviral therapies to enhance immune responses and improve clinical outcomes [19].

The development of frameworks such as TagHort, which enhances the transparency of inflammation prediction models, has also been noteworthy. Utilizing food-based models, TagHort has demonstrated effectiveness in improving the interpretability of complex inflammatory processes, instrumental in understanding and predicting leukotriene-mediated inflammation [11].

Recent research emphasizes the intricate roles of leukotriene pathways in various inflammatory processes, revealing their critical involvement in immune cell activation and recruitment, particularly in conditions like asthma and tumor-associated inflammation. These pathways, involving leukotriene synthesis from arachidonic acid, are essential for mediating inflammatory responses and play significant roles in chronic diseases linked to stress and immune dysregulation, emphasizing their importance in pulmonary and extrapulmonary manifestations of inflammation, including those observed in COVID-19 [43, 8, 44, 11, 15]. Innovative therapeutic strategies targeting these pathways present promising prospects for managing inflammatory diseases.

4 Leukotrienes and the Immune Response

Leukotrienes significantly influence immune responses, impacting immune cell dynamics, cytokine production, and signaling pathways. They are integral to both innate and adaptive immunity, playing active roles rather than being passive elements in immune regulation. This section examines how leukotrienes modulate immune cell dynamics, cytokine production, and immune signaling pathways, highlighting their implications for health and disease.

4.1 Leukotrienes and Immune Cell Dynamics

Leukotrienes, notably leukotriene B4 (LTB4) and cysteinyl leukotrienes (CysLTs), are pivotal lipid mediators that coordinate immune responses by directing immune cell recruitment, activation, and function. As illustrated in Figure 4, leukotrienes play key roles in immune dynamics, emphasizing their involvement in immune cell recruitment, interactions within immune signaling pathways, and potential therapeutic insights through computational modeling. LTB4 serves as a strong chemoattractant, enhancing the acute inflammatory response by guiding neutrophils and other immune cells to inflammation sites, crucial for pathogen clearance [24]. Leukotrienes interact with immune signaling pathways, where TIRAP, a key adaptor protein in Toll-like receptor signaling, exhibits roles in both pro-inflammatory and regulatory pathways, illustrating the complexity of leukotriene-mediated immune responses [49]. CysLTs, including LTC4, LTD4, and LTE4, intensify cytokine effects like interleukin-33 (IL-33) on type 2 innate lymphoid cells (ILC2), aggravating allergic reactions in asthma [14]. Cytokines are crucial in immune responses, as seen in Hepatitis B virus (HBV) infection, where they mediate immune reactions and control viral replication [40]. The interplay of pro-inflammatory and anti-inflammatory signals regulates immune cell behavior, balancing inflammatory and regulatory pathways [50]. Leukotrienes also contribute to chronic immune activation in conditions like chronic fatigue syndrome (CFS), with persistent immune responses potentially driven by Epstein-Barr virus (EBV) infections [26]. Computational modeling advancements, including cellular automata simulations, demonstrate how medication adjustments can alter immune system behavior by changing response thresholds, highlighting the therapeutic potential of targeting leukotriene pathways to modulate immune dynamics and improve clinical outcomes [51].



Figure 4: This figure illustrates the key roles of leukotrienes in immune dynamics, highlighting their involvement in immune cell recruitment, interactions within immune signaling pathways, and potential therapeutic insights through computational modeling.

4.2 Cytokine Production and Regulation

Leukotrienes are crucial in regulating cytokine production, influencing various immune pathways during the inflammatory response. Their interaction with cytokine networks involves both amplification and modulation of immune responses. TIRAP exemplifies this complexity by interacting with multiple signaling partners, affecting cytokine production and regulation, thus maintaining the balance in immune modulation [52]. Cytokines like IL-10 and TNF are vital for dendritic cell maturation, with leukotrienes playing a significant role in this process [53]. The interplay between leukotrienes and cytokines is further complicated by the multifaceted nature of immune responses, where different components can have synergistic or antagonistic effects on viral control [37]. The time-dependent nature of immune responses is critical for predicting cytokine production and immune cell behavior,

particularly in tumor dynamics studies [54]. Recent research has advanced our understanding of coronavirus pathogenesis, identifying therapeutic targets within cytokine and leukotriene pathways, pivotal for controlling viral replication and mitigating inflammatory damage [1].

4.3 Leukotrienes in Immune Signaling Pathways

Leukotrienes are essential in immune signaling pathways, synthesized from arachidonic acid, and modulating various immune cell activities. They critically influence both innate and adaptive immune responses, particularly in asthma, affecting immune cell recruitment and activation such as neutrophils and ILC2s. By enhancing cytokine effects like IL-33, leukotrienes contribute to airway inflammation and hyperresponsiveness, presenting potential therapeutic targets for asthma management [43, 45]. Leukotriene signaling interacts with specific receptors on immune cells, such as BLT1 and CysLT1, mediating LTB4 and CysLTs effects. These interactions enhance inflammatory responses by promoting immune cell recruitment and activation, regulated by key signaling molecules like TIRAP and C-reactive protein (CRP) [21, 45, 52, 10]. The binding of leukotrienes to their receptors activates downstream signaling cascades involving mitogen-activated protein kinases (MAPKs) and NF-B, regulating gene expression related to inflammation and immune responses. Quantitative modeling frameworks have advanced understanding of leukotriene-mediated immune interactions, emphasizing the statistical nature of immune recognition and response [38]. By integrating experimental data with computational approaches, researchers elucidate the complex regulatory networks governing leukotriene signaling and its impact on immune cell dynamics. Recent studies highlight leukotrienes' role in modulating cytokine production and immune cell behavior, particularly in asthma pathogenesis, where leukotriene and cytokine network interactions amplify inflammatory signals and promote sustained immune activation characterized by eosinophilia and lung inflammation [45, 10]. This interplay is crucial in chronic inflammatory diseases, where dysregulated leukotriene signaling contributes to persistent inflammation and tissue damage. Understanding leukotriene pathways is vital for developing targeted therapies to modulate leukotriene activity, particularly in inflammatory and immune-mediated diseases such as asthma, where dysregulation contributes to disease severity. Targeting the LTB4-BLT1 pathway may improve therapeutic outcomes, offering innovative treatment strategies for these conditions [43, 13, 44, 22].

4.4 Diseases Involving Leukotriene-Mediated Immune Dysregulation

Leukotrienes are pivotal in diseases characterized by immune dysregulation, where their aberrant production or signaling contributes to disease progression. In neuroinflammatory conditions like Alzheimer's and multiple sclerosis, leukotrienes facilitate glial cell overactivation, which can lead to neurotoxicity and exacerbate disease pathology [6]. The therapeutic potential of clusterzymes in modulating leukotriene activity in neuroinflammation necessitates further in vivo studies [16]. In oncology, leukotrienes are implicated in immune dysregulation within tumor microenvironments. Time delay inclusions in immune response models significantly alter tumor growth dynamics, suggesting targeting leukotriene-mediated signaling pathways as a viable therapeutic strategy [55]. The intricate interactions between leukotrienes and immune cells, particularly macrophages, require nuanced understanding for effective cancer therapies [9]. Leukotrienes also play a significant role in metabolic disorders such as obesity and diabetes. The vagus nerve's involvement in immune dysregulation during fetal inflammation, combined with leukotriene interactions, may influence metabolic pathways and glucose regulation [33]. This highlights leukotrienes' importance in coordinating immune and metabolic responses, central to metabolic diseases' pathophysiology [12]. In infectious diseases like COVID-19, leukotrienes contribute to the dysregulated immune response observed in severe cases. The immune response in COVID-19 exhibits quantitative and qualitative differences correlating with clinical outcomes, warranting further investigation into leukotriene pathway regulation to enhance patient management [39]. The potential use of montelukast, a leukotriene receptor antagonist, to improve clinical outcomes in COVID-19 underscores the need for clinical trials to evaluate its efficacy and explore alternative drug delivery methods [18]. The immune system's failure to differentiate between self-antigens and foreign antigens, leading to autoimmune diseases, is another critical area involving leukotrienes. This failure results in the destruction of healthy cells, emphasizing the necessity for therapeutic strategies to modulate leukotriene pathways and restore immune balance [40]. Leukotrienes are central to cytokine production and immune signaling pathways, with their interactions influencing the activation and resolution of inflammatory responses. The complexity

of leukotriene-mediated immune dysregulation across various diseases underscores the need for comprehensive research to develop effective therapeutic strategies [10].

5 Therapeutic Implications

5.1 Current Treatments and Efficacy of Leukotriene Inhibitors

Leukotriene inhibitors, like montelukast, target cysteinyl leukotriene receptors, playing a crucial role in managing inflammatory conditions such as asthma and allergic rhinitis by reducing bronchoconstriction and mucus production, thus improving respiratory function and decreasing exacerbations [22, 23]. In metabolic disorders, targeting the LTB4/LTB4R1 axis offers potential improvements in insulin sensitivity, highlighting leukotriene inhibitors' role in addressing inflammation-related metabolic dysregulation [56]. Efferent Vagus Nerve Stimulation (VNS) also shows promise in modulating systemic glucose levels and inflammatory responses [33].

In oncology, leukotriene pathways could enhance cancer therapy efficacy, and their integration with existing treatments may improve outcomes [15]. During the COVID-19 pandemic, montelukast has shown potential in alleviating symptoms by mitigating severe inflammatory responses [18]. Emerging strategies emphasize combining leukotriene inhibitors with model-free control strategies, utilizing intelligent controllers to manage inflammation without detailed patient models [35]. Systematic frameworks optimizing interventions in complex biological systems are promising for enhancing leukotriene inhibitor efficacy, ensuring tailored interventions [17]. Mathematical models analyzing treatment effects, like nucleoside analogues and interferons, could inform novel strategies targeting leukotriene pathways [37].

The efficacy of leukotriene inhibitors in reducing inflammation and improving clinical outcomes underscores their therapeutic value. Continued research and technological advancements are vital for refining strategies and developing effective, personalized treatments for inflammatory and immune-mediated conditions. Future explorations of stochastic elements and Vitamin D supplementation could further enhance treatment understanding and application [20].

5.2 Emerging Therapies Targeting Leukotriene Pathways

Emerging therapies targeting leukotriene pathways are increasingly recognized for managing inflammatory and immune-mediated diseases, given leukotrienes' roles in conditions like asthma and allergic rhinitis. Recent research has identified leukotriene receptors and biosynthetic enzymes as key therapeutic targets, paving the way for new pharmacological interventions, especially for patients unresponsive to conventional therapies [43, 13, 44, 22].

Advancements include selective inhibitors targeting 5-lipoxygenase (5-LOX) and associated proteins, essential in leukotriene biosynthesis, designed to reduce leukotriene production and mitigate pro-inflammatory effects [22]. Dual inhibitors targeting multiple leukotriene pathway components are also being explored to enhance outcomes. Computational modeling and systems biology have facilitated identifying novel therapeutic targets, enabling simulations of leukotriene interactions and predictions of therapeutic responses, invaluable for drug development [9]. Integrating multi-omics data may uncover new regulatory mechanisms and biomarkers, paving the way for personalized medicine approaches.

Natural compounds and phytochemicals are also being investigated as leukotriene pathway modulators, offering complementary approaches by modulating leukotriene activity and reducing inflammation [15]. Biologics, such as monoclonal antibodies targeting leukotriene receptors or downstream components, aim to inhibit leukotriene-mediated pathways, enhancing clinical outcomes in conditions like asthma and rheumatoid arthritis [43, 23, 13, 22, 45].

The development of therapies targeting leukotriene pathways represents a rapidly evolving field. Ongoing collaboration between academia and industry is essential for translating innovations into clinical applications that improve the management of inflammatory and immune-mediated diseases, particularly in chronic inflammation and stress-related conditions, as highlighted by studies on inflammation's role in sepsis and post-COVID-19 syndrome [8, 30, 35, 11, 7].

5.3 Innovative Approaches and Future Research Directions

Innovative approaches in studying leukotriene pathways leverage multi-omics data and computational tools to unravel inflammation and immune response dynamics. Multi-omics methodologies, integrating genomics, proteomics, and lipidomics, provide a comprehensive framework for elucidating leukotrienes' regulatory networks—potent lipid mediators in various inflammatory diseases. Advanced techniques like directed non-targeted mass spectrometry have identified over 500 distinct eicosanoids in human plasma, including 46 novel compounds, enhancing understanding of leukotriene biosynthesis and associated pathways, aiding in pinpointing new therapeutic targets and biomarkers for conditions like asthma, cardiovascular diseases, and cancer [43, 22, 13, 27]. These methodologies also capture immune response heterogeneity, supporting personalized medicine strategies that account for individual variations in immunometabolic interactions.

Future research should prioritize developing selective leukotriene biosynthesis inhibitors, exploring roles in emerging diseases, and personalizing treatment strategies based on lipid profiles [22]. Expanding network models to include additional immune interactions and validating findings with extensive experimental data, particularly in clinical scenarios like sepsis, are crucial for advancing understanding of leukotriene-mediated responses [51]. Improving model robustness against network misspecification and incorporating additional biological knowledge will enhance predictive power [50].

Exploring receptor interactions and dual receptor antagonists, particularly targeting cysteinyl leukotrienes (cysLTs) in eosinophilic disorders, represents a promising future research avenue [23]. Additionally, refining methods for automated identification and characterization of rare cell populations will enhance understanding of leukotriene pathways in the context of in vitro differentiation protocols [4].

Future research should also investigate additional drug interventions and side effects, as well as model adaptability to emerging viral variants [19]. The structural elucidation of BLT1 activation by LTB4 lays the groundwork for future anti-leukotriene drug design, underscoring the need for continued exploration of leukotriene receptor structures [24].

Investigating lymphatic dysfunction mechanisms and exploring novel therapeutic targets in lymphatic pathologies are critical areas for future exploration, particularly regarding inflammation's role in these conditions [25]. Incorporating factors like memory T cells and time delays in viral dynamics could enhance model realism and predictive power [40].

Refining models to integrate diverse data sources and exploring therapeutic implications of predicted macrophage behavior are essential for advancing understanding of leukotriene-mediated inflammation [26]. Future research should also assess the feasibility of implementing adaptive therapy in clinical trials, optimizing patient measurement frequency and targeted cytokines [7]. Additionally, integrating various types of tags and validating the TagHort framework across different domains and machine learning models may inform therapeutic implications in nutrition and inflammation [11].

Continued research in these areas will enhance understanding of leukotriene-mediated inflammation and immune responses, improving management of inflammatory and immune-mediated diseases. The integration of multi-omics approaches and advanced computational tools marks a significant advancement in exploring leukotriene pathways, crucial mediators in inflammation and asthma. This methodology not only enhances understanding of leukotriene biosynthesis and its associated metabolites but also opens avenues for groundbreaking discoveries related to their roles in various diseases. By leveraging these techniques, researchers can uncover novel therapeutic strategies targeting specific leukotriene receptors and biosynthetic enzymes, potentially leading to more effective treatments for conditions like asthma and other inflammatory disorders [43, 13, 22, 27].

6 Conclusion

This survey has delved into the intricate roles of leukotrienes, highlighting their significance as lipid mediators in inflammation and immune responses. As critical players in the pathogenesis of inflammatory and immune-mediated disorders, leukotrienes influence immune cell dynamics, cytokine production, and signaling pathways, underscoring their therapeutic potential. Their complex regulatory mechanisms are evident in conditions like asthma, arthritis, metabolic disorders, and cancer, where they modulate immune cell recruitment and cytokine signaling.

Leukotrienes' impact on mitochondrial function within immune cells further illustrates their role in cellular metabolism and immune regulation. Their interactions with gut microbiota contribute to immune homeostasis and pathogen control, emphasizing the importance of understanding these processes for developing targeted therapies, including probiotics and personalized microbiome interventions.

Recent studies underscore the importance of leukotriene pathways in managing severe infections, where strategic control can enhance inflammatory response regulation and clinical outcomes. The potential of NSAIDs in reducing breast cancer recurrences, especially in triple-negative cases, highlights the need for further clinical trials. Future research should focus on elucidating the complexities of immune responses in severe diseases, as current models often fall short in capturing these dynamics.

Exploring the effects of mechanical stress on cytokine dynamics and cartilage injury responses is crucial for advancing treatment strategies in inflammatory conditions. Additionally, understanding the vagus nerve's role in immunometabolic regulation during fetal inflammation could prevent neonatal conditions like obesity and NEC. The integration of mathematical models and computational tools offers promising prospects for predicting immune responses and informing therapeutic strategies, enhancing our understanding of leukotriene-mediated processes and guiding future research.

References

[1] Vibhuti Kumar Shah, Priyanka Firmal, Aftab Alam, Dipyaman Ganguly, and Samit Chattopadhyay. Overview of immune response during sars-cov-2 infection: lessons from the past. *Frontiers in immunology*, 11:1949, 2020.

[2] Simon West, Lloyd J. Bridge, Michael R. H. White, Pawel Paszek, and Vadim N. Biktashev. A method of 'speed coefficients' for biochemical model reduction applied to the nf-kappab system, 2014.

[3] Anusha Angajala, Sangbin Lim, Joshua B Phillips, Jin-Hwan Kim, Clayton Yates, Zongbing You, and Ming Tan. Diverse roles of mitochondria in immune responses: novel insights into immuno-metabolism. *Frontiers in immunology*, 9:1605, 2018.

[4] Ximena Ibarra-Soria, Wajid Jawaid, Blanca Pijuan-Sala, Vasileios Ladopoulos, Antonio Scialdone, David J Jörg, Richard CV Tyser, Fernando J Calero-Nieto, Carla Mulas, Jennifer Nichols, et al. Defining murine organogenesis at single-cell resolution reveals a role for the leukotriene pathway in regulating blood progenitor formation. *Nature cell biology*, 20(2):127–134, 2018.

[5] Joseph M Pickard, Melody Y Zeng, Roberta Caruso, and Gabriel Núñez. Gut microbiota: Role in pathogen colonization, immune responses, and inflammatory disease. *Immunological reviews*, 279(1):70–89, 2017.

[6] Shenbin Xu, Jianan Lu, Anwen Shao, John H Zhang, and Jianmin Zhang. Glial cells: role of the immune response in ischemic stroke. *Frontiers in immunology*, 11:294, 2020.

[7] Brenden K. Petersen, Jiachen Yang, Will S. Grathwohl, Chase Cockrell, Claudio Santiago, Gary An, and Daniel M. Faissol. Precision medicine as a control problem: Using simulation and deep reinforcement learning to discover adaptive, personalized multi-cytokine therapy for sepsis, 2018.

[8] Yun-Zi Liu, Yun-Xia Wang, and Chun-Lei Jiang. Inflammation: the common pathway of stress-related diseases. *Frontiers in human neuroscience*, 11:316, 2017.

[9] Oussema Souiai, Fatma Guerfali, Slimane Ben Miled, Christine Brun, and Alia Benkahla. In silico prediction of protein-protein interactions in human macrophages, 2015.

[10] Paolo Tieri, Silvana Valensin, Vito Latora, Gastone C. Castellani, Massimo Marchiori, Daniel Remondini, and Claudio Franceschi. Quantifying the relevance of different mediators in the human immune cell network, 2004.

[11] Fanyu Meng, Jules Larke, Xin Liu, Zhaodan Kong, Xin Chen, Danielle Lemay, and Ilias Tagkopoulos. Interpreting inflammation prediction model via tag-based cohort explanation, 2024.

[12] Boyang Wang, Pan Chen, Peng Zhang, and Shao Li. A network-based biomarkers discovery of cold/hot zheng chronic gastritis and cold/hot herbs of formulae, 2023.

[13] Takehiko Yokomizo, Motonao Nakamura, Takao Shimizu, et al. Leukotriene receptors as potential therapeutic targets. *The Journal of clinical investigation*, 128(7):2691–2701, 2018.

[14] Oliver Werz, Jana Gerstmeier, Stephania Libreros, Xavier De la Rosa, Markus Werner, Paul C Norris, Nan Chiang, and Charles N Serhan. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. *Nature communications*, 9(1):59, 2018.

[15] Wen Tian, Xinguo Jiang, Dongeon Kim, Torrey Guan, Mark R Nicolls, and Stanley G Rockson. Leukotrienes in tumor-associated inflammation. *Frontiers in pharmacology*, 11:1289, 2020.

[16] Haile Liu, Yonghui Li, Si Sun, Qi Xin, Shuhu Liu, Xiaoyu Mu, Xun Yuan, Ke Chen, Hao Wang, Kalman Varga, Wenbo Mi, Jiang Yang, and Xiao-Dong Zhang. Catalytically potent and selective clusterzymes for modulation of neuroinflammation through single-atom substitutions, 2020.

[17] Ionel Ciuperca, Laurent Pujo-Menjouet, Leon Matar-Tine, Nicolas Torres, and Vitaly Volpert. A qualitative analysis of a aβ-monomer model with inflammation processes for alzheimer's disease, 2022.

[18] Ludwig Aigner, Frank Pietrantonio, Diana Marisa Bessa de Sousa, Johanna Michael, Daniela Schuster, Herbert Anton Reitsamer, Horst Zerbe, and Michael Studnicka. The leukotriene receptor antagonist montelukast as a potential covid-19 therapeutic. *Frontiers in molecular biosciences*, 7:610132, 2020.

[19] Bishal Chhetri, D. K. K. Vamsi, Vijay M. Bhagat, Ananth V. S., Bhanu Prakash, Roshan Mandale, Swapna Muthusamy, and Carani B Sanjeevi. Crucial inflammatory mediators and efficacy of drug interventions in pneumonia inflated covid-19: An invivo mathematical modelling study, 2020.

[20] Susmita Roy, Krishna Shrinivas, and Biman Bagchi. Vitamin d sensitivity to the immune responses and autoimmunity: A chemical network model study, 2013.

[21] Nicola R Sproston and Jason J Ashworth. Role of c-reactive protein at sites of inflammation and infection. *Frontiers in immunology*, 9:754, 2018.

[22] Jesper Z Haeggström et al. Leukotriene biosynthetic enzymes as therapeutic targets. *The Journal of clinical investigation*, 128(7):2680–2690, 2018.

[23] Glaucia A Thompson-Souza, Isabella Gropillo, and Josiane S Neves. Cysteinyl leukotrienes in eosinophil biology: functional roles and therapeutic perspectives in eosinophilic disorders. *Frontiers in medicine*, 4:106, 2017.

[24] Na Wang, Xinheng He, Jing Zhao, Hualiang Jiang, Xi Cheng, Yu Xia, H Eric Xu, and Yuanzheng He. Structural basis of leukotriene b4 receptor 1 activation. *Nature communications*, 13(1):1156, 2022.

[25] Xinguo Jiang, Mark R Nicolls, Wen Tian, and Stanley G Rockson. Lymphatic dysfunction, leukotrienes, and lymphedema. *Annual review of physiology*, 80(1):49–70, 2018.

[26] Peter Ghazal, Steven Watterson, Kevin Robertson, and David C Kluth. The in silico macrophage: toward a better understanding of inflammatory disease, 2011.

[27] Jeramie D. Watrous, Teemu Niiranen, Kim A. Lagerborg, Mir Henglin, Yong-Jian Xu, Sonia Sharma, Ramachandran S. Vasan, Martin G. Larson, Aaron Armando, Oswald Quehenberger, Edward A. Dennis, Susan Cheng, and Mohit Jain. Directed non-targeted mass spectrometry and chemical networking for discovery of eicosanoids, 2018.

[28] Rukmini Kumar, Gilles Clermont, Yoram Vodovotz, and Carson Chow. Dynamics of acute inflammation, 2004.

[29] Ouassim Bara, Seddik Djouadi, Judy Day, and Suzanne Lenhart. Immune therapeutic strategies using optimal controls with l^1 and l^2 type objectives, 2017.

[30] Ghizal Fatima, Fadhil G. Al-Amran, and Maitham G. Yousif. Automated detection of persistent inflammatory biomarkers in post-covid-19 patients using machine learning techniques, 2023.

[31] Sirin W. Gangstad, Cilie W. Feldager, Jeppe Juul, and Ala Trusina. Noisy nfkb oscillations stabilize and sensitize cytokine signaling in space, 2012.

[32] Atanaska Dobreva, Renee Brady, Kamila Larripa, Charles Puelz, Jesper Mehlsen, and Mette S. Olufsen. A physiological model of the inflammatory-thermal-pain-cardiovascular interactions during a pathogen challenge, 2019.

[33] Mingju Cao, Shikha Kuthiala, Keven Jason Jean, Hai Lun Liu, Marc Courchesne, Karen Nygard, Patrick Burns, André Desrochers, Gilles Fecteau, Christophe Faure, and Martin G. Frasch. The vagus nerve regulates immunometabolic homeostasis in the ovine fetus near term: impact on terminal ileum, 2022.

[34] Jason M Graham. A measure of control for secondary cytokine-induced injury of articular cartilage: A computational study, 2013.

[35] Ouassim Bara, Michel Fliess, Cédric Join, Judy Day, and Seddik M. Djouadi. Model-free immune therapy: A control approach to acute inflammation, 2016.

[36] Kristen A. Windoloski, Elisabeth O. Bansgaard, Atanaska Dobreva, Johnny T. Ottesen, and Mette S. Olufsen. A unified model for the human response to lipopolysaccharide-induced inflammation, 2023.

[37] F. Fatehi Chenar, Y. N. Kyrychko, and K. B. Blyuss. Mathematical model of immune response to hepatitis b, 2018.

[38] Grégoire Altan-Bonnet, Thierry Mora, and Aleksandra M. Walczak. Quantitative immunology for physicists, 2019.

[39] Luis F García. Immune response, inflammation, and the clinical spectrum of covid-19. *Frontiers in immunology*, 11:1441, 2020.

[40] F. Fatehi, Y. N. Kyrychko, R. Molchanov, and K. B. Blyuss. Bifurcations and multi-stability in a model of cytokine-mediated autoimmunity, 2018.

[41] Kathleen P. Wilkie and Philip Hahnfeldt. Modeling the dichotomy of the immune response to cancer: Cytotoxic effects and tumor-promoting inflammation, 2013.

[42] Kamiya Tikoo, Shashank Mishr, V. Manivel, Kanury VS Rao, Parul Tripathi, and Sachin Sharma. Immunomodulatory role of an ayurvedic formulation on imbalanced immune-metabolics during inflammatory responses of obesity and pre-diabetic disease, 2012.

[43] Erwin W Gelfand. Importance of the leukotriene b4-blt1 and ltb4-blt2 pathways in asthma. In *Seminars in immunology*, volume 33, pages 44–51. Elsevier, 2017.

[44] Hayder M Al-Kuraishy, Ali I Al-Gareeb, Yaaser Q Almulaiky, Natalia Cruz-Martins, and Gaber El-Saber Batiha. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of covid-19: The enigmatic entity. *European journal of pharmacology*, 904:174196, 2021.

[45] Sean J Lund, Alex Portillo, Kellen Cavagnero, Rachel E Baum, Luay H Naji, Jana H Badrani, Amit Mehta, Michael Croft, David H Broide, and Taylor A Doherty. Leukotriene c4 potentiates il-33–induced group 2 innate lymphoid cell activation and lung inflammation. *The Journal of Immunology*, 199(3):1096–1104, 2017.

[46] Lulu Xu, Peiwu Qin, Zhenglin Chen, and Jiaqi Yang. Deep learning enables automated assessments of inflammatory response in zebrafish exposed to different pollutants, 2024.

[47] Maria Elena Gonzalez Herrero and Christian Kuehn. A qualitative mathematical model of the immune response under the effect of stress, 2021.

[48] Yishu Gong and Alexander Kiselev. Chemotactic reaction enhancement in one dimension, 2021.

[49] Susmita Roy, Krishna Shrinivas, and Biman Bagchi. A stochastic chemical dynamic approach to correlate autoimmunity and optimal vitamin-d range, 2014.

[50] Zhi Wei and Hongzhe Li. A hidden spatial-temporal markov random field model for network-based analysis of time course gene expression data, 2008.

[51] Kristen A. Windoloski, Susanne Janum, Ronan M. G. Berg, and Mette S. Olufsen. Characterization of differences in immune responses during bolus and continuous infusion endotoxin challenges using mathematical modeling, 2023.

[52] Sajjan Rajpoot, Kishore K Wary, Rachel Ibbott, Dongfang Liu, Uzma Saqib, Teresa LM Thurston, and Mirza S Baig. Tirap in the mechanism of inflammation. *Frontiers in Immunology*, 12:697588, 2021.

[53] Quentin Marcou, Irit Carmi-Levy, Coline Trichot, Vassili Soumelis, Thierry Mora, and Aleksandra M. Walczak. A model for the integration of conflicting exogenous and endogenous signals by dendritic cells, 2016.

[54] Giulio Caravagna, Alex Graudenzi, Marco Antoniotti, Giancarlo Mauri, and Alberto d'Onofrio. Effects of delayed immune-response in tumor immune-system interplay, 2012.

[55] D. Rodriguez-Perez, Oscar Sotolongo-Grau, Ramon Espinosa Riquelme, Oscar Sotolongo-Costa, J. Antonio Santos Miranda, and J. C. Antoranz. Tumors under periodic therapy – role of the immune response time delay, 2006.

[56] Wei Ying, Joshua Wollam, Jachelle M Ofrecio, Gautam Bandyopadhyay, Dalila El Ouarrat, Yun Sok Lee, Pingping Li, Olivia Osborn, Jerrold M Olefsky, et al. Adipose tissue b2 cells promote insulin resistance through leukotriene ltb4/ltb4r1 signaling. *The Journal of clinical investigation*, 127(3):1019–1030, 2017.

Disclaimer:

SurveyX is an AI-powered system designed to automate the generation of surveys. While it aims to produce high-quality, coherent, and comprehensive surveys with accurate citations, the final output is derived from the AI's synthesis of pre-processed materials, which may contain limitations or inaccuracies. As such, the generated content should not be used for academic publication or formal submissions and must be independently reviewed and verified. The developers of SurveyX do not assume responsibility for any errors or consequences arising from the use of the generated surveys.